Asia-Pacific PRA has offices in China, India, South Korea, Taiwan, Hong Kong, Singapore, New Zealand, and Australia, and offers additional clinical trial coverage in numerous other countries (i.e., Japan and Thailand) within the region.
PRA provides these regional services:
Regional Advantages: Asia-Pacific
- Population more than 2 billion
- Largest treatment and clinical trial naïve population
- Disease prevalence: common diseases of developing and tropical countries
- Infectious diseases, cardiovascular, cancer and increasingly, diseases more typical of Western societies
- Educated and experienced medical professionals eager to partake in clinical studies
- State-of-the-art study facilities
- Established and streamlined regulatory processes and requirements in almost all the countries to support global IND studies
- Countries within the region are adherent to ICH/GCP guidelines
- Economic slowdown in other parts of the world has spurred the need to outsource the R&D projects to emerging markets, such as Asia-Pacific
- Unmatched recruitment speed, typically half the time it takes in the US and Europe
- Costs are typically 70% of what they are in the US and Europe
PRA has the necessary local knowledge, investigator relationships, expertise and experience to help you run a successful trial in the Asia-Pacific region.
For more information on how PRA can make your next Asia-Pacific clinical trial a success, please click here to visit the contact us page.
